Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Byrd

Showing results (611-620 of 1,058) with videos related to

Pageof 106
Sort By:
Blood|March 8, 2011
The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemiaSarah E M Herman, Rosa Lapalombella, Amber L Gordon, et al.
The Journal of Biological Chemistry|December 3, 2015
Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) FunctionLi Ren, Amanda Campbell, Huiqing Fang, et al.
Leukemia & Lymphoma|March 6, 2009
Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphomaKristie A Blum, Mehdi Hamadani, Gary S Phillips, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2012
Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignanciesYicheng Mao, Georgia Triantafillou, Erin Hertlein, et al.
Blood|March 22, 2014
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicityHolbrook E Kohrt, Idit Sagiv-Barfi, Sarwish Rafiq, et al.
The Journal of Clinical Investigation|November 21, 2018
PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppressionShuai Dong, Bonnie K Harrington, Eileen Y Hu, et al.
Leukemia|July 21, 2016
Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2A-K Eisfeld, J Kohlschmidt, K Mrózek, et al.
Leukemia & Lymphoma|February 29, 2012
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B studyGerard Lozanski, Amy S Ruppert, Nyla A Heerema, et al.
American Journal of Hematology|October 10, 2022
Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinibAdam S Kittai, Ying Huang, Kyle A Beckwith, et al.
Blood|March 23, 2011
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765Sarah E M Herman, Amber L Gordon, Erin Hertlein, et al.
Pageof 106

Showing results (611-620 of 1,058) with videos related to

Sort By:
Pageof 106
Blood|March 8, 2011
The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemiaSarah E M Herman, Rosa Lapalombella, Amber L Gordon, et al.
The Journal of Biological Chemistry|December 3, 2015
Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) FunctionLi Ren, Amanda Campbell, Huiqing Fang, et al.
Leukemia & Lymphoma|March 6, 2009
Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphomaKristie A Blum, Mehdi Hamadani, Gary S Phillips, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2012
Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignanciesYicheng Mao, Georgia Triantafillou, Erin Hertlein, et al.
Blood|March 22, 2014
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicityHolbrook E Kohrt, Idit Sagiv-Barfi, Sarwish Rafiq, et al.
The Journal of Clinical Investigation|November 21, 2018
PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppressionShuai Dong, Bonnie K Harrington, Eileen Y Hu, et al.
Leukemia|July 21, 2016
Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2A-K Eisfeld, J Kohlschmidt, K Mrózek, et al.
Leukemia & Lymphoma|February 29, 2012
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B studyGerard Lozanski, Amy S Ruppert, Nyla A Heerema, et al.
American Journal of Hematology|October 10, 2022
Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinibAdam S Kittai, Ying Huang, Kyle A Beckwith, et al.
Blood|March 23, 2011
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765Sarah E M Herman, Amber L Gordon, Erin Hertlein, et al.
Pageof 106